QUOTE AND NEWS
PR Newswire  May 1  Comment 
QUEBEC CITY, May 1, 2012 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high value cancer diagnostic tests, issued a statement today commenting on the proposed acquisition of its commercial
PR Newswire  Mar 30  Comment 
FDA Approval of The First Molecular Prostate Cancer Test and Decreased Net Loss QUEBEC CITY, March 30, 2012 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests,
Marketwire  Mar 28  Comment 
NEW YORK, NY -- (Marketwire) -- 03/28/12 -- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of DiagnoCure, Inc. (TSX: CUR), a
PR Newswire  Feb 29  Comment 
Leading Clinicians Highlight Value of PCA3 Testing at Europe's Largest Urology Event QUEBEC CITY, Feb. 29, 2012 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high value cancer diagnostic
Canadian Business  Mar 11  Comment 
QUEBEC - Life sciences company DiagnoCure Inc. (TSX:CUR) says it lost $1.6 million in the first quarter as its revenues held steady.The
Canadian Business  Jan 19  Comment 
QUEBEC - Life sciences company DiagnoCure Inc. (TSX:CUR) says it lost money again last year but within expectations as it undertook to develop
Benzinga  Sep 13  Comment 
DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, today reported financial and operation results for the third quarter 2010 ended July 31, 2010. The Company...
Canadian Business  Sep 13  Comment 
QUEBEC - A 50 per cent drop in operating expenses despite lower revenue helped DiagnoCure Inc. post an improved third-quarter bottom
Canadian Business  Jun 9  Comment 
QUEBEC CITY, Que. - Laboratory services company DiagnoCure, Inc. (TSX:CUR) says its second quarter loss narrowed to $2.2 million as lower expenses
Canadian Business  Mar 17  Comment 
QUEBEC - DiagnoCure Inc. (TSX:CUR) says its losses deepened to $3.8 million in its first quarter as the life-sciences firm reworked the structure





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki